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Abstract
Background: The function of promyelocytic leukemia (PML) bodies is not well known but plays
an important role in controlling cell proliferation, apoptosis and senescence. This study was
undertaken to analyze the clinical significance of PML body expression in primary tumor samples
from malignant fibrous histiocytoma (MFH) and liposarcoma patients.
Methods:  We studied MFH and liposarcoma samples from 55 patients for PML bodies.
Fluorescent immunostaining of PML bodies was performed in the paraffin-embedded tumor
sections.
Results: PML body immunostaining was identified in 63.9% of MFH and 63.2% of liposarcoma
samples. PML body expression rates of all sarcoma cells were 1.5 ± 1.8% (range: 0–7.0) in MFH and
1.3 ± 1.4% (0–5.2) in liposarcoma samples. PML body expression (p = 0.0053) and a high rate of
PML body expression (p = 0.0012) were significantly greater prognostic risk factors for death than
the other clinical factors in MFH patients. All liposarcoma patients without expression of PML were
disease free at the end of the study.
Conclusion: Our study suggests that the presence of PML bodies may indicate a poor prognosis
for MFH and liposarcoma patients.
Background
PML was originally identified in leukemic blasts from
acute promyelocytic leukemia (APL) patients, and may
play a role in leukemogenesis [1-3]. PML bodies are
donut-shaped nuclear domains containing PML protein
[4], and are dynamic structures present in many normal
and neoplastic tissues [5]. PML bodies also seem to play a
multifaceted role in various cellular processes, including
cell proliferation [6,7], cellular senescence [8-10], apopto-
sis [11-13], and tumor suppression [14,15] so that the
function of PML bodies may well be an important con-
tributing factor in the pathogenesis of malignant tumors.
However, little is known concerning expression of PML
bodies in sarcomas, including whether or not expression
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can be used as a prognostic indicator of sarcomas. We
present the results of an analysis of the clinical signifi-
cance of PML body expression in primary tumor samples
from malignant fibrous histiocytoma and liposarcoma
patients.
Patients and methods
Among the patients who underwent surgery between
1989 and 2003, a total of 55 (36 MFHs and 19 liposarco-
mas) soft tissue sarcoma samples were obtained at the
time of surgery. Informed consent was obtained from
patients before surgery. The samples were fixed in 10%
formalin and embedded into paraffin for immunohisto-
chemistry. All clinical data are shown in Tables 1 and 2.
We collected all primary tumor samples by biopsy or
resection, and no patients had undergone chemotherapy
before surgical specimens were collected. Induction
chemotherapy was not used in any MFH and liposarcoma
patients. The tumor size was evaluated by measurement of
the largest diameter on MR images. Histological grades
were assigned according to the French Federation of Can-
cer Centers Sarcoma Group (FNCLCC) system based on
tumor differentiation, mitotic count and necrosis [16].
Surgical margins achieved were classified using the
method described previously [17]. We performed brachy-
therapy or external radiation therapy following conserva-
tive surgery for all patients who received marginal
resection.
PML body immunofluorescence
Immunostaining was performed on the paraffin-embed-
ded tumor sections. In short, the paraffin block was cut
into 8 um sections and placed onto slides, followed by
deparaffinization in xylene, then rehydration in alcohol.
The next step was to place them in 10 mmol of 80 degree
preheated Na citrate for 30 min. The slides were cooled,
rinsed in PBS, and ten percent BSA was used to block cells.
The slides were then incubated in the primary PML anti-
body, mouse monoclonal PML (PG-M3; Santa Cruz Bio-
technology, Inc., Santa Cruz, CA) (1:100 dilution)
overnight. Primary antibody was detected with FITC-con-
jugated gout anti-mouse IgG (1:200 dilution). Finally, the
slides were washed in PBS and mounted in vectashield
with DAPI.
Immunohistochemical evaluation
Two independent, blind observers evaluated immunos-
tained sections and the rates of stained cells were deter-
mined based on average values. For the evaluation of
immunostained cells, we examined at least 700 sarcoma
cells to determine whether their nuclei were positive for
PML body staining. For all analysis, the samples in which
stained cells made up 0.3% of the cells were regarded as
positive.
Statistical analysis
The cumulative prospective of overall survival was calcu-
lated using the method of Kaplan-Meier. Statistical signif-
icance of the differences between the survival curves was
evaluated using the log-rank test. Each prognostic factor
was divided into two groups based on an average value.
Data are presented as the mean ± SD. In all analyses, a p
value of < 0.05 was considered to indicate significance. All
analyses were performed by statistical package Statview,
Version 5.0 (Abacus Concepts, Berkley, CA).
Results
Immunofluorescence of PML body immunostaining on
paraffin sections identified 23 of 36 tumors (63.9%) in
MFHs and 12 of 19 (63.2%) in liposarcomas. PML body
expression rates of all sarcoma cells were 1.5 ± 1.8%
(range: 0–7.0) in MFHs and 1.3 ± 1.4% (0–5.2) in liposa-
rcomas (Figures 1 and 2, Tables 1 and 2).
Prognostic factors
MFH patients
With univariate analysis, PML body expression and a high
rate of PML body expression were significant prognostic
risk factors for death. The patients with PML body expres-
sion had a worse prognosis than those who did not (p =
0.0053) (Figure 3). Patients who had a higher than aver-
age expression rate of PML bodies had a worse prognosis
than other patients (p = 0.0012) (Figure 4). There were no
significant differences between the survival rate and other
factors (age: p = 0.919; gender: p = 0.297; histological
grade: p = 0.204; tumor size: p = 0.198; surgical margin: p
= 0.672; recurrence: p = 0.723).
Liposarcoma patients
All liposarcoma patients who had no PML body expres-
sion were disease free (Figure 5). The patients with local
recurrence had a worse prognosis than those who did not
(p = 0.0332). There were no significant differences
between patients who had a higher than verage expression
rate of PML bodies than other patients (p = 0.826). There
were no significant differences between the survival rate
and other factors (age: p = 0.0907; histological grade: p =
0.243; tumor size: p = 0.880; surgical margin: p = 0.458;
high rate of PML body expression: p = 0.826).
Discussion
PML protein is the product of the PML gene. It forms a
fusion protein with the retinoic acid receptor (RAR)-α due
to chromosome 15; 17 translocation in acute promyelo-
cytic leukemia (APL) [1-3,18]. It is highly likely that PML
protein plays a role in the regulation of transcriptional
activity [19]. Several papers have revealed the probability
that the PML/RAR-α fusion protein plays a key role in the
pathogenesis of APL by altering the structure of the PML
bodies [19-23]. The PML bodies are present in many kindsJ
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Table 1: Data of 36 patients with soft tissue MFH
No. Age 
(yrs)
Gender Site Histological 
subtype
Histological 
grade
Tumor size 
(cm)
Surgical 
margin
Recurrence Metastasis Prognosis Period 
(months)
PML (%) PML 
expression
1 53 male thigh stori-pleo 3 10 wide - + DOD 12 1.2 +
2 48 male thigh myxoid 3 13 marginal + - NED 80 0.0 -
3 76 female thigh stori-pleo 3 6.5 wide - + DOD 22 2.2 +
4 54 male thigh stori-pleo 3 9 wide - + DOD 12 0.5 +
5 49 male upperarm stori-pleo 3 10 marginal - + DOD 18 4.2 +
6 63 female axillar myxoid 2 4 wide - - CDF 28 2.0 +
7 82 male thigh stori-pleo 3 10.5 marginal - - CDF 80 1.0 +
8 66 female thigh stori-pleo 2 6 marginal - - CDF 60 0.0 -
9 75 male thigh stori-pleo 2 13 wide + - NED 35 1.7 +
10 45 female inguinal myxoid 1 7 marginal - - CDF 27 0.0 -
11 71 female lower leg myxoid 2 12 wide + + DOD 58 3.4 +
12 74 female thigh myxoid 2 4.5 wide - - CDF 73 0.4 +
13 53 male lower leg stori-pleo 3 10 wide - - CDF 30 0.0 -
14 78 female thigh stori-pleo 2 9 marginal - + DOD 9 2.0 +
15 35 male thigh stori-pleo 2 9 wide - - CDF 52 0.0 -
16 81 male thigh stori-pleo 3 8 wide - - CDF 26 2.0 +
17 84 male buttock stori-pleo 2 7.5 marginal - - CDF 26 0.0 -
18 57 female shoulder stori-pleo 2 5 wide - - CDF 62 0.0 -
19 76 female thigh stori-pleo 2 14 wide - + DOD 6 1.8 +
20 75 male thigh stori-pleo 3 8 wide - + DOD 10 3.0 +J
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21 57 male thigh stori-pleo 2 8.5 wide - - CDF 94 1.6 +
22 72 male thigh stori-pleo 2 15 marginal - + DOD 49 0.5 +
23 64 female buttock myxoid 3 11 marginal - + DOD 10 2.8 +
24 55 female thigh myxoid 2 8 wide - + DOD 21 7.0 +
25 59 female shoulder stori-pleo 2 12 marginal + + DOD 47 6.4 +
26 74 male thigh myxoid 2 9 wide - + DOD 27 0.0 -
27 46 male thigh stori-pleo 3 5.5 wide - - CDF 98 2.0 +
28 73 male thigh stori-pleo 2 5.5 wide - - CDF 112 1.0 +
29 62 female forearm myxoid 3 10 wide - - CDF 138 0.0 -
30 49 male upperarm stori-pleo 2 5.5 wide - - CDF 87 1.0 +
31 85 male thigh stori-pleo 3 11.5 marginal - - CDF 106 0.0 -
32 58 female buttock stori-pleo 3 10.5 marginal + + DOD 6 3.4 +
33 73 male thigh stori-pleo 2 6 wide - - CDF 112 0.0 -
34 71 female lower leg myxoid 2 12 marginal + - NED 65 0.0 -
35 73 female lower leg myxoid 2 7 wide - - CDF 25 1.2 +
36 45 female thigh myxoid 2 6.5 marginal - - CDF 29 0.0 -
stori-pleo: storiform-pleomorphic
CDF: continuous disease free
NED: no evidence of disease
DOD: dead of disease
Table 1: Data of 36 patients with soft tissue MFH (Continued)J
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Table 2: Data of 19 patients with liposarcoma
No. Age 
(yrs)
Gender Site Histological 
subtype
Histological 
grade
Tumor size 
(cm)
Surgical 
margin
Recurrence Metastasis Prognosis Period 
(months)
PML (%) PML 
expression
1 35 female popliteal myxoid 2 14 marginal - - CDF 65 0.0 -
2 50 female thigh myxoid 3 6 wide - - CDF 55 2.2 +
3 48 female forearm myxoid 2 8 marginal - - CDF 12 3.0 +
4 66 female lower leg dedifferentiate
d
3 8 marginal - - CDF 56 0.0 -
5 66 male upper arm myxoid 3 11 wide - - CDF 40 0.0 -
6 60 male thigh myxoid 2 16 wide - - CDF 47 1.4 +
7 74 male thigh myxoid 3 8 wide - + DOD 27 1.2 +
8 60 male thigh pleomorphic 3 10 wide - - CDF 132 0.0 -
9 51 male thigh round cell 3 9 wide - + DOD 12 2.1 +
10 66 male shoulder myxoid 2 8 wide - - CDF 70 2.0 +
11 68 male thigh myxoid 3 12 marginal - - CDF 120 0.0 -
12 43 female thigh myxoid 2 8 wide - - CDF 60 0.0 -
13 47 male forearm dedifferentiate
d
3 11 marginal - + DOD 12 1.2 +
14 62 female thigh myxoid 2 15 wide - - CDF 62 1.7 +
15 67 female thigh myxoid 2 15 wide - - CDF 60 0.4 +
16 63 male thigh pleomorphic 2 12 marginal - - CDF 54 2.0 +
17 73 female buttock myxoid 2 8 wide - - CDF 65 0.0 -
18 52 female thigh myxoid 3 6 wide - - CDF 49 1.5 +
19 48 male thigh myxoid 2 20 marginal + + DOD 15 5.2 +Journal of Experimental & Clinical Cancer Research 2008, 27:73 http://www.jeccr.com/content/27/1/73
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of tissues but not in all normal and tumor tissues [5]. It
has become apparent that PML is an important contribut-
ing factor in the pathogenesis of malignant tumors [24].
Terris et al. reported that PML bodies are not restricted to
APL but may be extended to other types of tumor and may
be linked to cell proliferation [25]. In our present study,
PML body immunostaining was identified in 23 of 36
MFHs (63.9%) and in 12 of 19 (63.2%) liposarcomas.
Therefore, sarcomas also may influence PML bodies and
PML may play an important role for tumorigenesis in sar-
comas.
In our study, PML body expression (p = 0.0053) and a
high rate of PML body expression (p = 0.0012) were sig-
nificant prognostic risk factors for death in MFH patients,
and all liposarcoma patients without expression of PML
were alive at the end of the study. The prognosis for
patients with sarcomas depends on the histological grade,
tumor size and local recurrence [26]. However, in our
present study, the PML body expression for patients corre-
lates more strongly with a worse prognosis than these clin-
ical factors, so that the presence of PML bodies indicated
the likelihood of poor outcomes in patients with soft tis-
sue sarcomas.
PML immunostaining on paraffin sections of MFH (patient  No.23) × 1000 Figure 1
PML immunostaining on paraffin sections of MFH 
(patient No.23) × 1000.
PML immunostaining on paraffin sections of liposarcoma  (patient No.7) × 1000 Figure 2
PML immunostaining on paraffin sections of liposar-
coma (patient No.7) × 1000.
Kaplan-Meier analysis of the association between survival and  the presence of PML expression in MFH samples Figure 3
Kaplan-Meier analysis of the association between sur-
vival and the presence of PML expression in MFH 
samples. The patients with PML body expression had a 
worse prognosis than those who did not (p = 0.0053).
Kaplan-Meier analysis of the association between survival and  the rate of PML expression in MFH samples Figure 4
Kaplan-Meier analysis of the association between sur-
vival and the rate of PML expression in MFH samples. 
Patients who had a higher than average expression rate of 
PML bodies had a worse prognosis than other patients (p = 
0.0012).Journal of Experimental & Clinical Cancer Research 2008, 27:73 http://www.jeccr.com/content/27/1/73
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Several studies indicate that overexpression of PML pro-
tein inhibits cell cycle progression leading to G1/S arrest,
suppresses some forms of oncogenic transformation and
promotes apoptosis [27-29]. Also, recent study suggests
that the PML protein may play a critical role in the sup-
pression of angiogenesis in tumors [30]. However, in con-
trast, some report suggests that increased expression of
PML was observed in several carcinoma cells and might be
functionally related to cellular growth [25], indicating all
PML will not be functionally equivalent in various cases
[27]. The up-regulation of PML could be secondary to the
release of several cytokines [25]. In fact MFH cells secrete
high levels of IL-6 and elevation of the IL-6 occurs on
tumor recurrence [31,32]. Strong expression of the tumor
associated IL-6 was confirmed in liposarcoma cells [33].
Therefore, we hypothesize that increased expression of
PML in sarcomas may be secondary to the secretion of
cytokines and relate to cellular growth and proliferation.
There are two telomere maintenance mechanisms in
human tumors: telomerase activity and alternative length-
ening of telomeres (ALT) [34,35]. Some immortalized tel-
omerase-negative cell lines possess extremely long and
heterogeneous telomeres as an ALT, and a substantial pro-
portion of types of sarcomas have been reported to have
ALT without telomerase activity [36,37]. ALT cells are
characterized by ALT-associated PML bodies (APBs), and
APB is reported as a simple hallmark of ALT, although
some report suggests that APBs are not always essential for
ALT [38]. Several papers have revealed that ALT is a signif-
icant prognostic factor in sarcoma patients [39-41].
Although the expression of PML is not directly associated
with APB, the association of the ALT with the PML may
influence the prognosis of sarcomas. Our results are based
on a small number of samples, so additional research of
PML functions for sarcomas is warranted.
In summary, PML bodies may be a useful objective marker
in the assessment of sarcoma prognosis. Due to the fact
that more than 60% of sarcomas have PML body expres-
sion, PML may be associated with pathogenesis and/or
tumor behavior of sarcomas.
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